Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer.

IF 0.8 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Journal of the Pakistan Medical Association Pub Date : 2025-04-01 DOI:10.47391/JPMA.20168

Kheyal Azam Khalil, Maria Habib, Afshan Saeed Usmani, Muhammad Ansab Shah, Abdul Wahid Anwer, Aamir Ali Syed

{"title":"Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer.","authors":"Kheyal Azam Khalil, Maria Habib, Afshan Saeed Usmani, Muhammad Ansab Shah, Abdul Wahid Anwer, Aamir Ali Syed","doi":"10.47391/JPMA.20168","DOIUrl":null,"url":null,"abstract":"Objectives: To determine the impact of delay between neoadjuvant chemotherapy and cytoreductive surgery on progression-free survival and overall survival in ovarian cancer cases.Methods: The retrospective study was conducted at the Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan, and comprised data from January 2019 to January 2022 of women diagnosed with stage III high-grade serous ovarian cancer who received neoadjuvant chemotherapy and underwent subsequent interval debulking surgery. The patients were divided into groups A and B based on time to surgery within 6 weeks and time to surgery more than 6 weeks, respectively. The endpoint was taken as progression-free survival and overall survival on follow-up. Data was analysed using SPSS 27.Results: Of the 2,100 patients who underwent surgery for ovarian cancer, 118(5.6%) women with mean age 52.18±9.3 years (range: 28-73 years) were included; 53(45%) in group A and 65(55%) in group B. Overall recurrence rate in this cohort was 76(64.4%); 36 (67.9%) in group A and 40 (61.5%) in group B. The mean progression freesurvival was 15±1.5 months in group A and 18±2 months in group B (p=0.854). The mean overall survival across the sample was 44±1.8 months, and intergroup difference was not significant. (p=0.336).Conclusions: Delay in interval debulking surgery after neoadjuvant chemotherapy was not found to have a significant impact on progression-free survival and overall survival in ovarian cancer cases.","PeriodicalId":54369,"journal":{"name":"Journal of the Pakistan Medical Association","volume":"75 4","pages":"583-586"},"PeriodicalIF":0.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pakistan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47391/JPMA.20168","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To determine the impact of delay between neoadjuvant chemotherapy and cytoreductive surgery on progression-free survival and overall survival in ovarian cancer cases.

Methods: The retrospective study was conducted at the Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan, and comprised data from January 2019 to January 2022 of women diagnosed with stage III high-grade serous ovarian cancer who received neoadjuvant chemotherapy and underwent subsequent interval debulking surgery. The patients were divided into groups A and B based on time to surgery within 6 weeks and time to surgery more than 6 weeks, respectively. The endpoint was taken as progression-free survival and overall survival on follow-up. Data was analysed using SPSS 27.

Results: Of the 2,100 patients who underwent surgery for ovarian cancer, 118(5.6%) women with mean age 52.18±9.3 years (range: 28-73 years) were included; 53(45%) in group A and 65(55%) in group B. Overall recurrence rate in this cohort was 76(64.4%); 36 (67.9%) in group A and 40 (61.5%) in group B. The mean progression freesurvival was 15±1.5 months in group A and 18±2 months in group B (p=0.854). The mean overall survival across the sample was 44±1.8 months, and intergroup difference was not significant. (p=0.336).

Conclusions: Delay in interval debulking surgery after neoadjuvant chemotherapy was not found to have a significant impact on progression-free survival and overall survival in ovarian cancer cases.

查看原文本刊更多论文

新辅助化疗后间隔减容手术延迟对卵巢癌患者生存的影响。

目的：确定新辅助化疗和细胞减少手术之间的延迟对卵巢癌病例无进展生存期和总生存期的影响。方法：回顾性研究在巴基斯坦拉合尔Shaukat Khanum纪念癌症医院和研究中心的外科肿瘤科进行，包括2019年1月至2022年1月诊断为III期高级别浆液性卵巢癌的妇女的数据，这些妇女接受了新辅助化疗并随后进行了间隔减脂手术。根据6周内手术时间和6周以上手术时间分别分为A组和B组。终点为随访时的无进展生存期和总生存期。数据采用SPSS 27进行分析。结果：2100例接受手术治疗的卵巢癌患者中，118例（5.6%）为女性，平均年龄52.18±9.3岁（28-73岁）；A组53例（45%），b组65例（55%），总复发率76例（64.4%）；A组36例（67.9%），B组40例（61.5%）。A组平均无进展生存期为15±1.5个月，B组平均无进展生存期为18±2个月（p=0.854）。样本的平均总生存期为44±1.8个月，组间差异无统计学意义。(p = 0.336)。结论：新辅助化疗后间隔减容手术的延迟对卵巢癌病例的无进展生存期和总生存期没有显著影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Pakistan Medical Association Medicine-General Medicine

CiteScore

1.10

自引率

11.10%

发文量

983

审稿时长

3-6 weeks

期刊介绍： Primarily being a medical journal, JPMA publishes scholarly research focusing on the various fields in the areas of health and medical education. It publishes original research describing recent advances in health particularly clinical studies, clinical trials, assessments of pathogens of diagnostic importance, medical genetics and epidemiological studies. Review articles highlighting importance of various issues in the domain of public health, drug research and medical education are also accepted. As a leading journal of South Asia, JPMA remains cognizant of the recent advances in the rapidly growing fields of biomedical sciences, it invites and encourages scholars to write short reviews and invited editorials on the emerging issues. We particularly aim to promote health standards of developing countries by encouraging manuscript submissions on issues affecting the public health and health delivery services.